Advancing first-in-class gene therapies for inherited retinal diseases
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The company's pipeline comprises seven AAV-based gene therapy assets and a small-molecule therapy targeting conditions including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa, with one FDA-approved product and multiple late-stage clinical programs.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
